Treatment of biliary duct stones with a terpene preparation Biliary duct stones are often found in patients who present with gallbladder disease and are poor surgical risks. Retained stones may persist after cholecystectomy, despite recent developments in nonoperative methods of extraction and in-situ litholytic agents. When facilities for endoscopic papillotomy are lacking, reoperation is contraindicated or further procedures refused, and spontaneous passage is unlikely on grounds of stone size, an alternative approach is needed.
We used Rowachol (Rowa Ltd, Bantry, Ireland), a monoterpene mixture with cholelitholytic potential.'
Patients, methods, and results
We treated nine female and two male patients with radiotranslucent ductal stones of a diameter greater than 7 mm and absent, infrequent, or mild symptoms (group 1) and four postoperative patients with retained stones, whose elective reoperations were either refused or considered to be undesirable (group 2). Endoscopic papillotomy was not available at the start of the study. In group 1 three patients had previously undergone cholecystectomy and three had, or developed, non-functioning gall bladders.
Maintenance dosage of Rowachol was with three capsules daily (some patients started at higher doses); symptoms and liver function were monitored six-weekly. Intravenous cholangiography was repeated after six and 12 months.
Treatment was well tolerated, a slightly sore mouth in one case being the only side effect. Results of liver function tests remained normal in six patients and improved in four asymptomatic patients with initially abnormal values. Five patients developed transient abnormalities after attacks of colic or jaundice.
The two male patients were withdrawn, one after five months when surgery was recommended for increasing colic and jaundice, the other after seven months on his death from cardiac infarction. Thirteen patients, all female, took Rowachol for one year or until the stone dissolved, if this was earlier. One of these had bile-duct dilatation and recurrent jaundice; after repeated advice she eventually accepted surgery, but at cholecystectomy no duct stones were found. The The reasons why Rowachol should be more successful in ductal than gall-bladder5 disease are not clear. A flushing effect of the choleresis for which Rowachol is marketed may be contributory. 
Thirty-two patients with radiotranslucent stones in functioning gall bladders were treated with Rowachol (two or three capsules daily) and chenodeoxycholic acid (375 mg at bedtime). Six further patients were treated with the same dose of chenodeoxycholic acid alone, and 13 with Rowachol alone (three capsules daily). Patients were assessed clinically and biochemically every six weeks, and oral cholecystography was repeated after six and 12 months.
The combination was well tolerated: only one patient noticed bowel disturbance sufficient to prevent continued treatment. Hypertransaminasaemia occurred only in association with episodes of biliary colic, and only three patients had biliary symptoms severe enough to require surgery before completing six months' treatment. Two more patients elected to have surgery at six months rather than continue treatment. Medication was changed in three patients for other reasons, one before and two after six months. One patient developed a persistently non-functioning gall bladder within six months. Thus five patients were withdrawn before the first repeat cholecystogram was obtained and five afterwards. No patient voluntarily defaulted; total withdrawals were thus 10 out of 32 (31 %). All the patients taking single preparations completed six months' treatment. The table shows the results of the trial in terms of gall-stone dissolution.
Comment
Gall-stone dissolution was more common with the combined treatment than when either drug was used alone. The success rate is greater when patients are selected for analysis as they would be for treatment according to currently recommended practice.2 Thus, at no cost in terms of efficacy, we reduced the chenodeoxycholic acid dose requirement by almost two-thirds; this resulted in a great improvement in patient tolerance and reduced by half the total cost of treatment. Formal double-blind assessment of optimal dosage of chenodeoxycholic acid, alone and in combination with Rowachol, is now indicated. They are all three herbs of Jupiter and under Leo, all great cordials, and great strengtheners of nature. The leaves and roots are to very good purpose used in putrid and pestilential fevers, to defend the heart, and help to resist and expel the poison, or the venom of other creatures: the seed is of the like effect; and the seed and leaves are good to increase milk in women's breasts; the leaves, flowers, and seed, all or any of them, are good to expel pensiveness and melancholy; it helps to clarify the blood, and mitigate heat in fevers. The juice made into a syrup prevails much to all the purposes aforesaid, and is put, with other cooling, opening and cleansing herbs to open obstructions, and help the yellow jaundice, and mixed with Fumitory, to cool cleanse, and temper the blood thereby; it helps the itch, ringworms and tetters, or other spreading scabs or sores. The flowers candied or made into a conserve, are helpful in the former cases, but are chiefly used as a cordial, and are good for those that are weak in long sickness, and to comfort the heart and spirits of those that are in a consumption, or troubled with often swoonings, or passions of the heart. The distilled water is no less effectual to all the purposes aforesaid, and helps the redness and inflammations of the eyes, being washed therewith; the herb dried is never used, but the green; yet the ashes thereof boiled in mead, or honied water, is available against the inflammations and ulcers in the mouth or throat, to gargle it therewith; the roots of Bugloss are effectual, being made into a licking electuary for the cough, and to condensate thick phlegm, and the rheumatic distillations upon the lungs. (Nicholas Culpeper (1616-54) The Complete Herbal,
